FREMONT, Calif., June 3, 2016 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and cardio-renal diseases, today announced that
Jeremy S. Caldwell, Ph.D., Executive
Vice President and Chief Scientific Officer, will present an
overview of the Company during the 2016 BIO International
Convention at 11:30 a.m. PDT on
Tuesday, June 7, 2016 at the Moscone
Center in San Francisco, CA.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
minimally-systemic, small molecule therapeutics that work
exclusively in the gastrointestinal tract to treat gastrointestinal
and cardio-renal diseases. Ardelyx has developed a proprietary drug
discovery and design platform enabling it, in a rapid and
cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor, which it is evaluating for the treatment of
irritable bowel syndrome with constipation, or IBS-C, and
management of hyperphosphatemia in patients with end-stage renal
disease. In addition to tenapanor, Ardelyx is developing RDX227675,
a non-absorbed polymer for the treatment of hyperkalemia, or high
potassium, in kidney and heart disease patients. Ardelyx is also
advancing several research programs focused in gastrointestinal and
cardio-renal diseases. Ardelyx is located in Fremont, California. For more information,
please visit Ardelyx's website at www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-2016-bio-international-convention-300279298.html
SOURCE Ardelyx